Dividend-News

Is Pfizer The Best COVID Vaccine Play For Dividend Investors?

Published Wed, 18 Nov 2020 10:33:45 -0500 on Seeking Alpha

Seeking AlphaIs Pfizer The Best COVID Vaccine Play For Dividend Investors?Nov. 18, 2020 10:33 AM ET|| Includes: AZN, AZNCF, BNTX, JNJ, MRNA, PFEby: Seeking AlphaSeeking Alpha OfficialSummaryVaccine makers are in the spotlight, and several of them pay high dividend yields.
But which is the right choice for YOUR dividend portfolio?
We looked at PFE, JNJ, and AZN to see how they compare on factors like Dividend Safety, Growth, Yield, and Consistency.
Finally, says Big Pharma, there’s a light at the end of the tunnel. Phase 3 trials are underway for multiple vaccines to combat COVID-19: Pfizer (PFE) and BioNTech (BNTX) are nearing the finish line, as is another mRNA vaccine from Moderna (MRNA).
Each breakthrough sent the respective stocks soaring. And eight months into the pandemic, dozens of biotech stocks are flashing a “Bullish” or “Very Bullish” signal in our Premium Quant system.
Plus, let’s not forget: Big Pharma is a perennial source of dividends as well, offering some of the best yields in the market.
But the question for income investors is always: Is that dividend safe? And will it grow?
Our Quant team, led by Steven Cress, has devised a new system specifically to answer these questions.
Find an explainer on our NEW Dividend Grades here. The algorithm behind them combs through dozens of metrics (both historic and forward-looking) each day. Then it assigns four simple letter grades for each dividend stock.
These Dividend Grades are best used to compare companies within a given sector. After all, trends in dividend yield, dividend history and the like can vary widely across different industries.
Within the pharmaceutical industry, some of the leading dividend payers also boast Phase 3 vaccines for COVID. That would be Pfizer, Johnson & Johnson (JNJ), and AstraZeneca (AZN).
And our Dividend Grades are picking up some very interesting intelligence on these stocks. Let’s take a look.
Pfizer: The Best Yield
... Read more